{
  "first_published_at": "2010-10-11", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON096804", 
  "title": "Rosiglitazone: recommended withdrawal from clinical use", 
  "tags": "{\"parsed_therapeutic\": [\"endocrinology-diabetology-metabolism\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Endocrinology, diabetology and metabolism\"]}", 
  "_document_number": 184, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/withdrawal_icon.png", 
  "therapeutic_area": [
    "endocrinology-diabetology-metabolism"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Rosiglitazone: recommended withdrawal from clinical use</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: October 2010</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--The European Committee on Medicinal Products for Human Use has recommended the suspension of the marketing authorisations of rosiglitazone (Avandia, Avandamet)-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>The European Committee on Medicinal Products for Human Use has recommended the suspension of the marketing authorisations of rosiglitazone (Avandia, Avandamet) across the European Union.<br></p><p>The UK Commission on Human Medicines has reviewed the available data and has concluded that there is an increased cardiovascular risk for rosiglitazone. It has not been possible to identify additional measures that would reduce the cardiovascular risk or to identify a patient population in whom the benefits continue to outweigh the risks. The Commission has therefore concluded that the benefits of rosiglitazone no longer outweigh its risks.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals and patients:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Prescribers should put in place a system to ensure that all patients are reviewed and changed to another suitable treatment in line with NICE recommendations</li>\r\n\t\t\t\t<li>While this change could happen at the next routine appointment, prescribers may wish to see patients sooner rather than later in order to reduce patient anxiety</li>\r\n\t\t\t\t<li>Patients who are concerned should not stop their treatment but should contact the healthcare professional supervising their diabetic treatment</li>\r\n\t\t\t</ul></div><p>Further information is available <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON094121\" target=\"_blank\">on our website</a>; see also <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON096743\" target=\"_blank\">letter for healthcare professionals sent Oct 1, 2010</a>.&nbsp;</p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Oct 2010, vol 4 issue 3: S1.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>The European Committee on Medicinal Products for Human Use has recommended the suspension of the marketing authorisations of rosiglitazone (Avandia, Avandamet) across the European Union.<br></p><p>The UK Commission on Human Medicines has reviewed the available data and has concluded that there is an increased cardiovascular risk for rosiglitazone. It has not been possible to identify additional measures that would reduce the cardiovascular risk or to identify a patient population in whom the benefits continue to outweigh the risks. The Commission has therefore concluded that the benefits of rosiglitazone no longer outweigh its risks.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals and patients:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Prescribers should put in place a system to ensure that all patients are reviewed and changed to another suitable treatment in line with NICE recommendations</li>\r\n\t\t\t\t<li>While this change could happen at the next routine appointment, prescribers may wish to see patients sooner rather than later in order to reduce patient anxiety</li>\r\n\t\t\t\t<li>Patients who are concerned should not stop their treatment but should contact the healthcare professional supervising their diabetic treatment</li>\r\n\t\t\t</ul></div><p>Further information is available <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON094121\" target=\"_blank\">on our website</a>; see also <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON096743\" target=\"_blank\">letter for healthcare professionals sent Oct 1, 2010</a>.&#160;</p><p>&#160;</p><p><em>Article citation: Drug Safety Update Oct 2010, vol 4 issue 3: S1.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2010-10-01", 
  "date_last_modified": "2010-10-11", 
  "_assets": [], 
  "_item_id": 184, 
  "summary": "", 
  "body": "Article date: October 2010\n\nThe European Committee on Medicinal Products for Human Use has recommended the suspension of the marketing authorisations of rosiglitazone (Avandia, Avandamet) across the European Union.  \n\n\nThe UK Commission on Human Medicines has reviewed the available data and has concluded that there is an increased cardiovascular risk for rosiglitazone. It has not been possible to identify additional measures that would reduce the cardiovascular risk or to identify a patient population in whom the benefits continue to outweigh the risks. The Commission has therefore concluded that the benefits of rosiglitazone no longer outweigh its risks.\n\nAdvice for healthcare professionals and patients:  \n  \n  * Prescribers should put in place a system to ensure that all patients are reviewed and changed to another suitable treatment in line with NICE recommendations  \n  * While this change could happen at the next routine appointment, prescribers may wish to see patients sooner rather than later in order to reduce patient anxiety  \n  * Patients who are concerned should not stop their treatment but should contact the healthcare professional supervising their diabetic treatment  \n  \nFurther information is available [on our website](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON094121); see also [letter for healthcare professionals sent Oct 1, 2010](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON096743). \n\n \n\nArticle citation: Drug Safety Update Oct 2010, vol 4 issue 3: S1.\n"
}